GENB Valuation

Generate Biomedicines, Inc. (GENB) is now in the Fair zone, suggesting that its current forward PS ratio of NaN is considered Fairly compared with the five-year average of --. The fair price of Generate Biomedicines, Inc. (GENB) is between -- to -- according to relative valuation method.

GENB's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Generate Biomedicines, Inc. (GENB) is between -- to -- according to relative valuation method.

The average P/S ratio for GENB's competitors is 5838.29, providing a benchmark for relative valuation. Generate Biomedicines, Inc. Corp (GENB) exhibits a P/S ratio of --, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

As of Mar 02 2026, Generate Biomedicines, Inc. (GENB) has a P/B ratio of NaN. This indicates that the market values GENB at NaN times its book value.

As of Mar 02 2026, Generate Biomedicines, Inc. (GENB) has a FCF Yield of NaN%. This means that for every dollar of Generate Biomedicines, Inc.'s market capitalization, the company generates NaN cents in free cash flow.

As of Mar 02 2026, Generate Biomedicines, Inc. (GENB) has a Forward P/E ratio of NaN. This means the market is willing to pay $NaN for every dollar of Generate Biomedicines, Inc.'s expected earnings over the next 12 months.

As of Mar 02 2026, Generate Biomedicines, Inc. (GENB) has a Forward P/S ratio of NaN. This means the market is valuing GENB at $NaN for every dollar of expected revenue over the next 12 months.